Google Expands AI Partnership With Singapore Government 
Anthropic Revenue Surge Signals Strong AI Market Momentum in 2026 
Japan Airlines Signs 10-Year Boeing 787 Maintenance Deal With GE Aerospace 
Tencent Shares Jump 4% as AI Models Move Toward Paid Commercial Services 
Texas Sues Meta Over WhatsApp Encryption Claims 
Walmart Stock Falls Despite Strong Q1 Revenue Beat and E-Commerce Growth 
GameStop Raises eBay Stake to 6.6% as Ryan Cohen Pushes $56 Billion Takeover Bid 
OpenAI Expands Globally with First Overseas AI Lab in Singapore 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
H.B. Fuller Eyes Advanced Medical Solutions in Potential £600M Takeover Deal 
Samsung Union Confirms 18-Day Strike After Failed Wage Talks 
SpaceX Eyes AI Computing Expansion Ahead of Historic IPO 
Lam Research Expands AI-Powered Semiconductor Tools and Arizona Operations 
X Corp Loses Legal Battle Over Australia Child Safety Fine 
Intuit Raises Full-Year Forecast After Strong Q3 Earnings Despite Stock Drop 
Nvidia Beats Earnings Expectations as AI Demand Drives Record Growth 
Roche is buying Genmark Diagnostics for $1.8 billion or €1.5 billion, and this was revealed on Monday, March 15. The price is for the full acquisition of the US-based molecular diagnostic tests maker.
The numbers in Roche’s newest investment
Roche’s price offer is equivalent to the price of $24.05 per share in an all-cash deal. This also showed a premium of 43% on GenMark’s closing stock on Feb. 10, just before the speculations about Roche’s plans to purchase GenMark made rounds, as per CNBC.
The Swiss pharmaceuticals manufacturer company decided to buy the leading provider of multiplex molecular diagnostic solutions so it can expand the business and make its presence in the diagnostics sector.
“Acquiring GenMark Diagnostics will broaden our molecular diagnostics portfolio to include solutions that can provide lifesaving information quickly to patients and their healthcare providers in the fight against infectious diseases,” Thomas Schinecker, Roche’s chief executive officer, said via press release.
It was added that the acquisition that was approved by the respective board of directors of Roche and GenMark Diagnostics is expected to be completed within the second quarter of 2021. Once the negotiations are done, the latter’s main operations will not be moved but will continue in its current office location in Carlsbad, California.
The setup in the merger deal
The terms in the merger agreement were partly disclosed, and one clause states that Roche will immediately and directly initiate a tender offer to purchase all outstanding stocks of GenMark’s shares.
At any rate, GenMark’s portfolio will complement and further enhance Roche’s molecular diagnostics portfolio. It is also expected that the Swiss company will widen its global network reach when it starts to distribute GenMark’s items and products.
“As a part of Roche, we can accelerate our mission to enable rapid diagnosis of infectious disease to improve patient outcomes,” CEO of GenMark Diagnostics, Scott Mendel, said. “Together with Roche’s diagnostics healthcare solutions, we will be able to provide a full suite of molecular diagnostic solutions to customers around the world.”
Finally, Mendel added that GenMark is thrilled to become part of the globally known Roche. He is confident that they made the right decision to move forward with the Swiss firm.
